Checkpoint inhibitor therapy and psoriasis: a case series
Clin Exp Dermatol
.
2023 Mar 1;48(3):254-256.
doi: 10.1093/ced/llac095.
Authors
Khawar Hussain
1
,
Alpa Kanji
2
,
Shirin Zaheri
3
,
Dalila Malek
4
,
Monica Terlizzo
5
,
Justin Weir
6
,
Samra Turajlic
7
,
Louise Fearfield
1
7
Affiliations
1
Department of Dermatology, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
2
Department of Dermatology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
3
HCA Healthcare UK, London, UK.
4
Department of Dermatology, Southend University Hospital, Basildon, UK.
5
Department of Histopathology, Royal Marsden Hospital, London, UK.
6
Department of Histopathology, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
7
Skin and Melanoma Unit, Royal Marsden Hospital, London, UK.
PMID:
36763756
DOI:
10.1093/ced/llac095
No abstract available
Publication types
Letter
MeSH terms
Humans
Nivolumab
Psoriasis* / therapy
Substances
Nivolumab
Grants and funding
29911/CRUK_/Cancer Research UK/United Kingdom